• i_mail

© Copyright Morphocell Technologies Inc 2018

NEWS

April 15, 2019

Maggie Bywater assumes new role as special adviser

Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.

MONTREAL, April 15, 2019 - Morphocell Technologies Inc.announces that, as initially planned, Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. As a co-founder, Maggie played an integral role in the start-up of the corporation and successfully led it through the completion of a seed financing investment round. 

 

Maggie will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations. Her extensive experience in managing growth and bringing new classes of products to market in the global biotech industry will be valuable to Morphocell.

 

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.  

About Morphocell

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues targeting liver disease. Founded in April 2018, Morphocell Technologies aims at bringing to market the first effective treatment for acute, chronic and acute-on-chronic liver failure. www.morphocell.com

 

 

Media Contact Morphocell Technologies:

info@morphocell.com